THERAPEUTIC TARGETS

MARKET OPPORTUNITY

SAM

TAM

PAM

Addressing a Global Health Challenge Impacting 1 in 4 People

Potential Addressable Market:

PAD: 150 - 200M patients, (18 M in U.S.)
Coronary artery disease: 315M patients
Heart valve calcification: ~25M patients
Chronic Kidney Disease ~500M patients have vascular calcification
Stroke 93M patients

Total Addressable Market:

PAD patients with arterial calcification requiring treatment
34-57M (30-50% of total PAD population)

Market Context:

With PAD drugs, and endovascular interventions such as stents, balloons, atherectomy, & IVL, ELT-101 can

facilitate use
render them unnecessary
be used when those calcify or fail

PERIPHERAL ARTERY DISEASE

Peripheral Artery Disease (PAD) is a serious cardiovascular condition characterized by narrowing and hardening of leg arteries, causing pain, loss of mobility, and increasing the risk of complications leading to amputation. Current treatment options are limited and often invasive, leaving a critical need for innovative therapies. No therapy reverses calcification where it starts in the artery wall.

Peripheral Vascular Disease _ Southwest_.jpeg

CARDIOVASCULAR DISEASE

Cardiovascular disease encompasses a range of disorders affecting the heart and blood vessels, including coronary artery disease, stroke, and PAD. Calcification of arteries plays a major role in these conditions by stiffening vessel walls, impairing blood flow, and triggering adverse cardiovascular events. Reversal of arterial calcification can significantly improve patient outcomes and reduce healthcare burdens globally.

CALCIFICATION & ELASTIN

Arterial calcification (grey sections on upper image) is a major risk factor that leads to and complicates many cardiovascular conditions. It results from the deposition of calcium phosphate crystals in artery walls, often triggered by damage to elastin; a vital protein that provides elasticity to arteries. Middle image shows where elastin is located in arteries. Lower image shows healthy and damaged elastin.

As elastin degrades, calcification and chronic inflammation accelerate, causing arteries to stiffen and lose their flexibility. Targeting calcification at the site of damaged elastin is key to restoring vascular function.

Diabetes, COPD, & Kidney Disease patients face higher risk of complications & amputation due to calcification.
Calcification is primary reason for the failures of stents, angioplasty, & atherectomy interventions, requiring costly & risky revascularization procedures
Current treatments such as revascularization, lithotripsy, mechanical removal, and drugs each have limitations, leaving a major unmet need.

Image Credits: Top Image Philips Medical Bottom image Fraunhofer.

Bottom image shows elastin in a six-year-old on left and elastin in a 90-year-old right. This degradation process occurs in everybody.